Holen Sie sich die Stockscreener-App
0.7397
5.33%
0.0374
Handel nachbörslich:
.74
0.0003
+0.04%
Schlusskurs vom Vortag:
$0.7023
Offen:
$0.72
24-Stunden-Volumen:
1.02M
Relative Volume:
0.31
Marktkapitalisierung:
$129.31M
Einnahmen:
$400.57M
Nettoeinkommen (Verlust:
$9.21M
KGV:
18.49
EPS:
0.04
Netto-Cashflow:
$146.36M
1W Leistung:
-1.24%
1M Leistung:
+18.92%
6M Leistung:
-82.92%
1J Leistung:
-88.11%
1-Tages-Spanne:
$0.7001
$0.7529
1-Wochen-Bereich:
$0.6861
$0.784
52-Wochen-Spanne:
$0.5271
$7.105
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Firmenname
Ironwood Pharmaceuticals Inc
Sektor
Telefon
617-621-7722
Adresse
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Vergleichen Sie IRWD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.7397 | 129.31M | 400.57M | 9.21M | 146.36M | 0.04 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-08 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-09 | Eingeleitet | Jefferies | Buy |
| 2023-09-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-02 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Eingeleitet | Northland Capital | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Sell |
| 2018-05-09 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2017-07-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Eingeleitet | Wells Fargo | Outperform |
| 2017-04-07 | Bestätigt | Mizuho | Buy |
| 2017-02-22 | Bestätigt | Barclays | Equal Weight |
| 2016-11-04 | Bestätigt | Mizuho | Buy |
| 2016-10-24 | Bestätigt | Wedbush | Neutral |
| 2016-10-10 | Bestätigt | Mizuho | Buy |
| 2016-09-27 | Bestätigt | WallachBeth | Hold |
Alle ansehen
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood Pharma Elects Directors at Annual Meeting - TipRanks
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Is A Good Stock To Invest In - Stocksregister
Ameriprise Financial Inc. Trims Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com Canada
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $4.78 - Defense World
Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Pacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Ironwood: Q1 Earnings Snapshot - New Haven Register
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook By Investing.com - Investing.com India
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook - Investing.com
Ironwood Pharmaceuticals (IRWD) Maintains LINZESS Sales Outlook Amid Pricing Challenges | IRWD Stock News - GuruFocus
Ironwood (IRWD) Reports Q1 Revenue Shortfall, Ending Quarter with Increased Cash Reserves | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Ironwood Pharmaceuticals Q1 2025 Earnings: EPS of -$0.23 Misses Estimate, Revenue Falls Short at $41.14 Million - GuruFocus
Ironwood Pharmaceuticals Reports First Quarter 2025 Results | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals Reports First Quarter 2025 Results - Business Wire
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo
Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView
Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus
Finanzdaten der Ironwood Pharmaceuticals Inc-Aktie (IRWD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ironwood Pharmaceuticals Inc-Aktie (IRWD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gaskins Tammi L | Chief Commercial Officer |
May 16 '25 |
Sale |
0.58 |
2,563 |
1,487 |
242,596 |
2.01%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):